Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5CLM

1,4-Oxazine BACE1 inhibitors

Summary for 5CLM
Entry DOI10.2210/pdb5clm/pdb
DescriptorBeta-secretase 1, N-{3-[(3R)-5-amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl]phenyl}-5-chloropyridine-2-carboxamide, IODIDE ION, ... (5 entities in total)
Functional Keywordsbace1 protease inhibitor, orally bioavailable, brain penetrant, proteros biostructures gmbh, hydrolase
Biological sourceHomo sapiens (Human)
Cellular locationMembrane; Single-pass type I membrane protein: P56817
Total number of polymer chains1
Total formula weight45389.01
Authors
Primary citationRombouts, F.J.,Tresadern, G.,Delgado, O.,Martinez-Lamenca, C.,Van Gool, M.,Garcia-Molina, A.,Alonso de Diego, S.A.,Oehlrich, D.,Prokopcova, H.,Alonso, J.M.,Austin, N.,Borghys, H.,Van Brandt, S.,Surkyn, M.,De Cleyn, M.,Vos, A.,Alexander, R.,Macdonald, G.,Moechars, D.,Gijsen, H.,Trabanco, A.A.
1,4-Oxazine beta-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
J.Med.Chem., 58:8216-8235, 2015
Cited by
PubMed Abstract: 1,4-Oxazines are presented, which show good in vitro inhibition in enzymatic and cellular BACE1 assays. We describe lead optimization focused on reducing the amidine pKa while optimizing interactions in the BACE1 active site. Our strategy permitted modulation of properties such as permeation and especially P-glycoprotein efflux. This led to compounds which were orally bioavailable, centrally active, and which demonstrated robust lowering of brain and CSF Aβ levels, respectively, in mouse and dog models. The amyloid lowering potential of these molecules makes them valuable leads in the search for new BACE1 inhibitors for the treatment of Alzheimer's disease.
PubMed: 26378740
DOI: 10.1021/acs.jmedchem.5b01101
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.61 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon